Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT00569504 Recruiting - Schizophrenia Clinical Trials

Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics

Start date: December 2007
Phase: N/A
Study type: Observational

The purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.

NCT ID: NCT00567099 Recruiting - Schizophrenia Clinical Trials

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

Start date: August 2003
Phase: N/A
Study type: Interventional

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia prior to initiation with aripiprazole treatment and after three months of taking the antipsychotic medication aripiprazole.

NCT ID: NCT00564096 Recruiting - Schizophrenia Clinical Trials

Transcranial Magnetic Stimulation (TMS) in Schizophrenia

Start date: October 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Until recently stimulation of nervous tissue deeper than approximately 2 cm from the scalp (will hence be called non-deep TMS) was not possible (3).A new coil ("H"-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel ) capable of stimulating more than twice this depth (Up to 5 cm)was recently developed.Deep TMS is using this h-coil. Auditory hallucinations are reported by 50% to 70% of patients with schizophrenia and generally consist of spoken speech or "voices." . Patients usually describe the hallucinatory experience as distressing, consistent with evidence that the most common hallucinated utterances are abusive terms,contributing in up to 25% of the cases to a serious suicide attempt.The neuroanatomical basis of auditory hallucinations is thought to involve increasing blood flow of the speech perception areas of the brain, such as the superior temporal cortex of the dominant hemisphere as well as right and left superior temporal cortex.Brain imaging studies of patients with auditory hallucinations have revealed an active area in the right and left superior temporal cortex, Broca's area, and the left temporoparietal cortex. Shergill et al. reported the presence of active areas in the anterior cingulate cortex, right thalamus, left hippocampus, and parahippocampal cortex when subjects were experiencing auditory hallucinations. Magnetic Stimulation of Left Temporoparietal Cortex suggest that the mechanism of auditory hallucinations involves activation of the left temporoparietal cortex.Reasons to believe that right frontotemporal TMS stimulation cortex can ameliorate auditory hallucinations include evidence that right temporoparietal stimulation achieved significant changes in the frequency of auditory hallucinations,in the patients with auditory hallucinations an increase in blood flow is noted in the right superior temporal gyrus,right temporal lobe activation during auditory hallucination,effect of rTMS can spread to the opposite hemisphere through interhemispheric connections,some evidence that brain circuits involved in the production of auditory hallucinations and symptoms of schizophrenia are widespread and not confined in the left temporoparietal cortex.Deep TMS can reach brain structures as deep as 5 cm whereas non-deep TMS can reach structures less than half that distance. As deep brain structures such as thalamic, limbic and paralimbic regions have been shown to be activated during auditory hallucinations and suspected to play a role in the pathogenesis of auditory hallucinations, their stimulation may attenuate auditory hallucinations. Non-deep TMS can stimulate the cortex but not the neuronal pathways connecting it to deeper brain structures and which stimulation may be additive.

NCT ID: NCT00563017 Recruiting - Schizophrenia Clinical Trials

Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone

Start date: October 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection. The major advantage of long-acting injection over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among schizophrenic and is a frequent cause of relapse.

NCT ID: NCT00525863 Recruiting - Clinical trials for Chronic Schizophrenia

Oxygen Therapy in Schizophrenia

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Due to intense ATP-consuming processes in the brain, a high level of brain energy supply is required. A popular hypothesis regarding the pathogenesis and pathophysiology of schizophrenia postulates hypofunction of neuronal circuits in the prefrontal and limbic-temporal areas. An emerging body of data suggests that impaired energy metabolism due to mitochondrial dysfunction plays a role in the pathophysiology of schizophrenia. Under normal conditions cellular metabolic rate, i.e. oxygen and glucose consumption, increases proportionally with any increase in neuronal activity. The impaired energy metabolism due to mitochondrial dysfunction and frontal lobe hypofunction might be improved by increasing O2 supply to the brain. Oxygen-enriched air inhalation has been shown to increase brain oxygen supply. Hyperoxia therapy is a useful tool in the treatment of neurological and neurotrauma deficits. We therefore suggest a randomized double blind cross-over study of enriched inspired O2 partial pressure in schizophrenia. It is surprising given the numerous findings on reduced energy metabolism in schizophrenia that simple treatment with inspired enriched oxygen has not been studied.

NCT ID: NCT00480844 Recruiting - Schizophrenia Clinical Trials

Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone

Start date: October 2008
Phase: Phase 4
Study type: Interventional

In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia. Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in schizophrenia and with fewer side effects.

NCT ID: NCT00468533 Recruiting - Clinical trials for Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome

The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial

Start date: May 2006
Phase: Phase 4
Study type: Interventional

A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.

NCT ID: NCT00465920 Recruiting - Schizophrenia Clinical Trials

Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis

mCBT
Start date: May 2007
Phase: Phase 2
Study type: Interventional

In the last decade cognitive behavioural therapy (CBT) approaches for patients with schizophrenia have been developed, which where especially designed to reduce severity of positive symptoms, readmission rates, treatment non-compliance and disability. Although CBT addresses the key problems of early onset psychoses (EOP)treatment and first evaluations of CBT in adults with schizophrenia are promising, no experience with CBT in adolescents with EOP are available. Therefore the present study is conducted to develop a modified CBT (mCBT) for adolescents with EOP, to explore its acceptance and feasibility and to provide data for a realistic estimation of achievable effect size. Patients are randomized to receive either mCBT+TAU or TAU over a 9 month period. mCBT is an individual outpatient treatment of 20 session and 5 psychoeducational sessions with parents. Follow-ups for two years every 6 months are planned.

NCT ID: NCT00465283 Recruiting - Schizophrenia Clinical Trials

Donepezil Double Blind Trial for ECT Memory Disfunction

Start date: May 2007
Phase: Phase 4
Study type: Interventional

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

NCT ID: NCT00418912 Recruiting - Schizophrenia Clinical Trials

Family Study in Schizophrenia

Start date: March 2007
Phase: N/A
Study type: Observational

Schizophrenia is a severe mental illness which is considered to have, among other, a genetic etiology. One of the most efficient tools in genetic-psychiatry is the investigation of multiplex families. The current study will identify patients of multiplex families and to map their family connections and the presence of mental illnesses among family members.